Operating profit before amortization: Metagenomi (MGX)
Is it worth investing in Metagenomi, Inc. (MGX), which utilizes natural enzymes to bypass gene-editing patents? The quarterly EBITDA provides the answer, with the figure standing at 0.00. The business relies on external contractors (CRO/CMO) to conduct tests. Furthermore, Metagenomi, Inc. (MGX) lacks pricing power, as it generates revenue solely through early-stage research partnerships.
%20Profit%20before%20payment%20of%20interest%2C%20taxes%20and%20amortization&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_MGX_-_Metagenomi-Inc._-_Profit-before-payment-of-interest-taxes-and-amortization "MGX Metagenomi, Inc: Profit before interest, taxes and amortization in the range 11/23/2025 - 11/14/2026 | 👁️GURU.Markets👁️")
Metagenomi - analytical breakdowns and key metrics (MGX)
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- balance sheet net asset value indicators:
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Metagenomi, Inc.|MGX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Metagenomi Inc.|MGX - Company Aggregate Debts|Debts to Net Assets Metagenomi|MGX - Company Long-Term Debt|Company Short-Term Indebtedness Metagenomi|Quick Liquidity Indicator metagenomi.co
- earnings and market multiples details:
MGX - Net Income|Company Profit Forecast Metagenomi, Inc.|MGX - Price to Earnings Ratio|Projected Price to Earnings metagenomi.co|MGX - PEG Multiple|Enterprise Value to EBITDA Multiple Metagenomi|MGX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Metagenomi|MGX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months metagenomi.co|MGX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Metagenomi, Inc.
- sales and revenue data:
Summary company analytics:MGX Metagenomi Therapeutics
Conservative capital demands absolute cash flow transparency to assess business viability amid tight monetary policy. This indicator measures operating earnings before interest and taxes, allowing for an evaluation of Metagenomi, Inc. (MGX) and its ability to generate resources for growth. A strong scientific core and strategic alliances support the company's resilience, which is clearly reflected in the aggregate EBITDA of Metagenomi, Inc. (MGX).
Competitors of Metagenomi, Inc. (MGX)
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN - Profit before payment of interest, taxes and amortization|IONS (ionispharma.com) - Operating profit before amortization|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Avidity Biosciences Inc (RNA)|Profit before payment of interest, taxes and amortization CRISPR Therapeutics Corp|Operating profit before deduction of amortization GeneDx Corp (WGS)|Operating profit EBITDA RARE|Operating income before deduction of amortization beamtx.com|Sarepta - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|Operating income before deduction of amortization Intellia Corp NTLA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Operating profit before amortization BLFS|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Operating profit before deduction of amortization SION (Sionna Pharma)|Operating income before deduction of amortization Prime Medicine Bio|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|QURE - Operating profit before deduction of amortization|MeiraGTx - Operating profit EBITDA|Operating profit before depreciation charges REGENXBIO Inc (RGNX)|SLDB (Solid Bio) - Operating profit before deduction of amortization|Operating profit before amortization OCGN|PACB (Pacific Biosciences) - Operating profit EBITDA|Operating profit before amortization BNTC (benitec.com)|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Rocket Pharma - Operating profit before amortization|Operating profit EBITDA FDMT (4D Molecular Therapeutics Inc)|Operating profit EBITDA Lexeo Therapeutics Inc. LXEO|KRRO - Profit before payment of interest, taxes and amortization|editasmedicine.com (EDIT) - Operating profit before deduction of amortization|SLN: Operating profit EBITDA|Profit before interest, taxes and amortization ProQR Therapeutics (PRQR)|Operating profit before deduction of amortization CDXS|SGMO (Sangamo BioSciences) - Company profit before taxes, interest and amortization|Operating profit EBITDA NAUT|Operating profit EBITDA precisionbiosciences.com (DTIL)|Operating profit EBITDA GBIO (Generation Bio)|Operating profit before depreciation charges Boundless Bio Inc.|Exicure Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Imunon, Inc.|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Profit before interest, taxes and amortization Bionano BNGO|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Operating profit before deduction of amortization bluebird bio, Inc BLUE|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|OMIC: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS: Operating profit EBITDA|TBIO - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
